218 related articles for article (PubMed ID: 30134961)
21. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.
Castillo-Carranza DL; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Gerson JE; Singh G; Estes DM; Barrett AD; Dineley KT; Jackson GR; Kayed R
J Neurosci; 2014 Mar; 34(12):4260-72. PubMed ID: 24647946
[TBL] [Abstract][Full Text] [Related]
22. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.
Chai X; Wu S; Murray TK; Kinley R; Cella CV; Sims H; Buckner N; Hanmer J; Davies P; O'Neill MJ; Hutton ML; Citron M
J Biol Chem; 2011 Sep; 286(39):34457-67. PubMed ID: 21841002
[TBL] [Abstract][Full Text] [Related]
23. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
[TBL] [Abstract][Full Text] [Related]
25. Phos-tau peptide immunization of amyloid-tg-mice reduced non-mutant phos-tau pathology, improved cognition and reduced amyloid plaques.
Benhamron S; Rozenstein-Tsalkovich L; Nitzan K; Abramsky O; Rosenmann H
Exp Neurol; 2018 May; 303():48-58. PubMed ID: 29432723
[TBL] [Abstract][Full Text] [Related]
26. Tau silencing by siRNA in the P301S mouse model of tauopathy.
Xu H; Rösler TW; Carlsson T; de Andrade A; Fiala O; Hollerhage M; Oertel WH; Goedert M; Aigner A; Höglinger GU
Curr Gene Ther; 2014; 14(5):343-51. PubMed ID: 25687501
[TBL] [Abstract][Full Text] [Related]
27. Detecting tau in serum of transgenic animal models after tau immunotherapy treatment.
d'Abramo C; Acker CM; Schachter JB; Terracina G; Wang X; Forest SK; Davies P
Neurobiol Aging; 2016 Jan; 37():58-65. PubMed ID: 26508157
[TBL] [Abstract][Full Text] [Related]
28. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
29. Organotypic brain slice cultures of adult transgenic P301S mice--a model for tauopathy studies.
Mewes A; Franke H; Singer D
PLoS One; 2012; 7(9):e45017. PubMed ID: 22984603
[TBL] [Abstract][Full Text] [Related]
30. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
31. Tau-proximity ligation assay reveals extensive previously undetected pathology prior to neurofibrillary tangles in preclinical Alzheimer's disease.
Bengoa-Vergniory N; Velentza-Almpani E; Silva AM; Scott C; Vargas-Caballero M; Sastre M; Wade-Martins R; Alegre-Abarrategui J
Acta Neuropathol Commun; 2021 Jan; 9(1):18. PubMed ID: 33509301
[TBL] [Abstract][Full Text] [Related]
32. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.
Dai CL; Hu W; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2018 Jan; 10(1):13. PubMed ID: 29386065
[TBL] [Abstract][Full Text] [Related]
33. Endogenous tau aggregates in oligodendrocytes of rTg4510 mice induced by human P301L tau.
Ren Y; Lin WL; Sanchez L; Ceballos C; Polydoro M; Spires-Jones TL; Hyman BT; Dickson DW; Sahara N
J Alzheimers Dis; 2014; 38(3):589-600. PubMed ID: 24028867
[TBL] [Abstract][Full Text] [Related]
34. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models.
Sankaranarayanan S; Barten DM; Vana L; Devidze N; Yang L; Cadelina G; Hoque N; DeCarr L; Keenan S; Lin A; Cao Y; Snyder B; Zhang B; Nitla M; Hirschfeld G; Barrezueta N; Polson C; Wes P; Rangan VS; Cacace A; Albright CF; Meredith J; Trojanowski JQ; Lee VM; Brunden KR; Ahlijanian M
PLoS One; 2015; 10(5):e0125614. PubMed ID: 25933020
[TBL] [Abstract][Full Text] [Related]
35. Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.
Schroeder SK; Joly-Amado A; Gordon MN; Morgan D
J Neuroimmune Pharmacol; 2016 Mar; 11(1):9-25. PubMed ID: 26538351
[TBL] [Abstract][Full Text] [Related]
36. Ultrasound-mediated delivery of novel tau-specific monoclonal antibody enhances brain uptake but not therapeutic efficacy.
Bajracharya R; Cruz E; Götz J; Nisbet RM
J Control Release; 2022 Sep; 349():634-648. PubMed ID: 35901857
[TBL] [Abstract][Full Text] [Related]
37. AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy.
Ising C; Gallardo G; Leyns CEG; Wong CH; Jiang H; Stewart F; Koscal LJ; Roh J; Robinson GO; Remolina Serrano J; Holtzman DM
J Exp Med; 2017 May; 214(5):1227-1238. PubMed ID: 28416651
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy for tauopathies.
Gu J; Sigurdsson EM
J Mol Neurosci; 2011 Nov; 45(3):690-5. PubMed ID: 21739165
[TBL] [Abstract][Full Text] [Related]
39. A walk through tau therapeutic strategies.
Jadhav S; Avila J; Schöll M; Kovacs GG; Kövari E; Skrabana R; Evans LD; Kontsekova E; Malawska B; de Silva R; Buee L; Zilka N
Acta Neuropathol Commun; 2019 Feb; 7(1):22. PubMed ID: 30767766
[TBL] [Abstract][Full Text] [Related]
40. Specificity of anti-tau antibodies when analyzing mice models of Alzheimer's disease: problems and solutions.
Petry FR; Pelletier J; Bretteville A; Morin F; Calon F; Hébert SS; Whittington RA; Planel E
PLoS One; 2014; 9(5):e94251. PubMed ID: 24788298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
